flipper44, as usual your take contains some astute points.
I agree on the surprise on the result against significant residual disease after NWBO disclosing tumor debulking was an important factor, but the difference between levels of resection can be dramatic and there is no quantification here. So this result is actually good news.
The 1 piece of data that is perplexing is the 20% survival at 3 yrs for the 232 treated population, which I expected to be higher, given the previously reported blended 28%. The missing population in the 20% is the original placebo group comprised of the 64 crossovers and the 35 non-crossovers. Of the 64 crossovers only 6 patients survived to 3 yrs, so only 10% of that group were included in the 28%. This leaves only the 35. Does this make sense to you? TIA
GLTA here, much to come and a review or two of the slides is highly recommended
Market Data 
Markets 
AI
